$OGEN
ORAGENICS INC

2024 Q4 Form 10-Q Financial Statement

#000149315224045067 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $7.466K
YoY Change -91.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.330M
YoY Change 9.46%
% of Gross Profit
Research & Development $879.0K $769.4K
YoY Change 14.26% -72.76%
% of Gross Profit
Depreciation & Amortization $10.00K
YoY Change -21.51%
% of Gross Profit
Operating Expenses $2.437M $2.102M
YoY Change 15.96% -47.97%
Operating Profit -$2.437M -$2.094M
YoY Change 16.37% -47.02%
Interest Expense $14.17K
YoY Change 171.04%
% of Operating Profit
Other Income/Expense, Net -$25.59K $81.56K
YoY Change -131.38% 127.08%
Pretax Income -$2.463M -$2.013M
YoY Change 22.36% -48.62%
Income Tax
% Of Pretax Income
Net Earnings -$2.463M -$2.013M
YoY Change 22.36% -48.62%
Net Earnings / Revenue -26960.69%
Basic Earnings Per Share -$0.38 -$0.85
Diluted Earnings Per Share -$0.38 -$0.85
COMMON SHARES
Basic Shares Outstanding 12.21M shares 5.581M shares 2.539M shares
Diluted Shares Outstanding 6.528M shares 2.356M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.770M
YoY Change -58.64%
Cash & Equivalents $3.144M $5.767M
Short-Term Investments
Other Short-Term Assets $2.010M
YoY Change 257.68%
Inventory
Prepaid Expenses $386.0K
Receivables
Other Receivables $35.10K
Total Short-Term Assets $4.113M $7.814M
YoY Change -47.36% -46.16%
LONG-TERM ASSETS
Property, Plant & Equipment $52.40K
YoY Change -60.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K
YoY Change
Total Long-Term Assets $1.091M $85.34K
YoY Change 1178.18% -83.83%
TOTAL ASSETS
Total Short-Term Assets $4.113M $7.814M
Total Long-Term Assets $1.091M $85.34K
Total Assets $5.204M $7.899M
YoY Change -34.12% -47.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $810.0K
YoY Change -7.01%
Accrued Expenses $65.66K $45.28K
YoY Change 45.02% -77.58%
Deferred Revenue
YoY Change
Short-Term Debt $490.0K
YoY Change 15.32%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.402M
YoY Change -6.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.402M
Total Long-Term Liabilities
Total Liabilities $2.127M $1.402M
YoY Change 51.67% -17.65%
SHAREHOLDERS EQUITY
Retained Earnings -$213.4M -$193.5M
YoY Change 10.32% 4.43%
Common Stock $9.388K $2.549K
YoY Change 268.3% -97.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.078M $6.497M
YoY Change
Total Liabilities & Shareholders Equity $5.204M $7.899M
YoY Change -34.12% -47.48%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.463M -$2.013M
YoY Change 22.36% -48.62%
Depreciation, Depletion And Amortization $10.00K
YoY Change -21.51%
Cash From Operating Activities -$1.500M
YoY Change -60.27%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $60.00K
YoY Change
Cash From Investing Activities $60.00K
YoY Change -262.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 730.0K
YoY Change -805.31%
NET CHANGE
Cash From Operating Activities -1.500M
Cash From Investing Activities 60.00K
Cash From Financing Activities 730.0K
Net Change In Cash -710.0K
YoY Change -81.87%
FREE CASH FLOW
Cash From Operating Activities -$1.500M
Capital Expenditures $0.00
Free Cash Flow -$1.500M
YoY Change -59.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
ORAGENICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3410522
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 750
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
200271 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7218795 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001174940
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity File Number
EntityFileNumber
001-32188
dei Entity Address Address Line1
EntityAddressAddressLine1
1990 Main Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Sarasota
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34236
dei City Area Code
CityAreaCode
813
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12212680 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3144049 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
969294 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4113343 usd
CY2024Q3 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2024Q3 us-gaap Assets
Assets
5204093 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1607114 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
519392 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2126506 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
1592723 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
9388 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
214912523 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213437047 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5204093 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3077587 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
769350 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2449234 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1558239 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1332562 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4754149 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2437280 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2101912 usd
us-gaap Operating Expenses
OperatingExpenses
7203383 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2437280 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2094446 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7203383 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9466 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25590 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
81561 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15412 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2462870 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2012885 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2462870 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2012885 usd
us-gaap Net Income Loss
NetIncomeLoss
-7218795 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 OGEN Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisable
shares
dei Local Phone Number
LocalPhoneNumber
286-7900
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OGEN
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3483501 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
382273 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3865774 usd
CY2023Q4 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9811 usd
CY2023Q4 us-gaap Assets
Assets
4966335 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1475667 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
312703 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9811 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1798181 usd
CY2024Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1592723 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9387547 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9387547 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3080693 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3080693 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3081 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207790604 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206218254 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3168154 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4966335 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7466 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37653 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
879041 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4448623 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3697609 usd
us-gaap Operating Expenses
OperatingExpenses
8146232 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8108579 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
50613 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
35106 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
171768 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
9971 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
14170 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18859 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18360 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
45118 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
46863 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25085 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-31659 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7908308 usd
us-gaap Net Income Loss
NetIncomeLoss
-7908308 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.70
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6528064 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6528064 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2356065 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2356065 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4857182 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4857182 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2136340 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2136340 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3168154 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69344 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1838601 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2450833 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2625266 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58220 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
948000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2305090 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1326396 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
330802 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3883259 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2462870 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3077587 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13009302 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
79966 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2844837 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10244431 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63628 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3050586 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7257473 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7257473 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-1591 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
404516 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
849808 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2012885 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6497321 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6497321 usd
us-gaap Net Income Loss
NetIncomeLoss
-7218795 usd
us-gaap Net Income Loss
NetIncomeLoss
-7908308 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
27391 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
22443 usd
us-gaap Share Based Compensation
ShareBasedCompensation
458366 usd
us-gaap Share Based Compensation
ShareBasedCompensation
546519 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
35104 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-49951 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1443563 usd
OGEN Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-9811 usd
OGEN Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-323103 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-9340 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
131449 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-572396 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9811 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6579029 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6188335 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
63715 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63715 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
430283 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
385329 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6669860 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
849808 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6239577 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
464479 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-339452 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5660141 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3483501 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11426785 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3144049 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5766644 usd
us-gaap Interest Paid Net
InterestPaidNet
18859 usd
us-gaap Interest Paid Net
InterestPaidNet
3347 usd
us-gaap Notes Assumed1
NotesAssumed1
636972 usd
us-gaap Notes Assumed1
NotesAssumed1
611109 usd
us-gaap Net Income Loss
NetIncomeLoss
-7218795 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6579029 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213437047 usd
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5600000 shares
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
7700000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zyPHVA8Hb4pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zq8ShpPPWvQe">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the condensed consolidated financial statements are estimates for research and development expenses and related prepaid and accrued expenses, which are based on the percentage of completion of the Company’s contracts with Contract Research Organizations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
386035 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
531701 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
334940 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
51558 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
47333 usd
CY2024Q3 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2023Q4 OGEN Prepaid Research And Development Expense Noncurrent
PrepaidResearchAndDevelopmentExpenseNoncurrent
1090750 usd
CY2024Q3 OGEN Prepaid Expense Deposits And Other Current Assets
PrepaidExpenseDepositsAndOtherCurrentAssets
2060044 usd
CY2023Q4 OGEN Prepaid Expense Deposits And Other Current Assets
PrepaidExpenseDepositsAndOtherCurrentAssets
1473023 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1513287 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1244947 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
65657 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
222739 usd
CY2024Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
28170 usd
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
7981 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1607114 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1475667 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
519392 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
312703 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
519392 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
312703 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8659071 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8659071 shares
OGEN Gross Proceeds Of Offering Percentage
GrossProceedsOfOfferingPercentage
0.0700 pure
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4450000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
260995 shares
CY2023Q4 OGEN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
82.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
530329 shares
OGEN Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
43862 shares
OGEN Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice
89.60
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
747462 shares
CY2024Q3 OGEN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
22.98
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1887167 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
244733 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.17
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M23D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
74559 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
799583 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
17146 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
28.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4667 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.52
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1022503 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y21D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
904853 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y11M19D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
330802 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
402805 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
458365 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
546399 usd
OGEN Unrecognized Compensation Costs Related To Stock Options
UnrecognizedCompensationCostsRelatedToStockOptions
195296 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y

Files In Submission

Name View Source Status
0001493152-24-045067-index-headers.html Edgar Link pending
0001493152-24-045067-index.html Edgar Link pending
0001493152-24-045067.txt Edgar Link pending
0001493152-24-045067-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
ogen-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
ogen-20240930_cal.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
ogen-20240930_def.xml Edgar Link unprocessable
ogen-20240930_lab.xml Edgar Link unprocessable
ogen-20240930_pre.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable